Molecular Tumor Board Case Series: Targeted Treatments For Cancer And Their Toxicities: Amivantamab-Induced Linear...

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Next-generation sequencing (NGS) enables targeted cancer treatments.
• Epidermal Growth Factor Receptor (EGFR) exon 20 insertion mutations are a specific target in lung adenocarcinoma.
• Balancing treatment efficacy with toxicity is crucial for patient survival.

Observation:

• A patient with recurrent lung adenocarcinoma harbored an EGFR exon 20 insertion mutation.
• The patient was treated with amivantamab, a targeted therapy for specific EGFR mutations.

Findings:

• Amivantamab treatment led to severe dermatologic toxicity in this patient.
• This adverse event underscores potential risks associated with targeted EGFR therapies.

Implications:

• Clinicians must carefully monitor for and manage toxicities associated with targeted agents like amivantamab.
• Understanding treatment-related toxicities is essential for optimizing patient outcomes in precision oncology.
• Further research may be needed to mitigate or predict severe adverse events in patients receiving EGFR-targeted therapies.